Team Up to Advance Bioelectronics

The Alliance for Advancing Bioelectronic Medicine (AABM) aims to play a unique convening role for the industry, mobilizing patients, physicians, and other stakeholders to advocate for the field, as well as to engage new audiences such as policy makers, investors, media, and the general public. MD+DI recently spoke with Barry Keenan, vice president of engineering at BioSig Technologies, a company that is one of the initial supporters of the AABM, about the growth and potential of the bioelectronic medicine market.
When asked why the bioelectronic market is important in healthcare, Keenan said that bioelectronic medicine has the potential to provide immediate relief for patients suffering from a number of chronic illnesses, without the side effects typically associated with drug therapy. “Many people believe it will replace a number of pharmacotherapies,” he said. “Bioelectronic medicine can treat locally by modulating parts of the central and peripheral nervous system—whereas with drug therapy, chemicals are released into the body that become systemic right away and can have intolerable side effects.”
Groups are also exploring bioelectronics in other innovative ways, he noted. For example, Keenan mentioned that there is currently research going on that could use bioelectronics to prevent type 1 diabetes. “This exciting research is at the early preclinical sta...

Source: MDDI - January 15, 2020 Category: Medical Devices Tags: Electronics Source Type: news